Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 28 references it cites were found in a registry or an index.

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

Open access
Hill, A., Khoo, S., Fortunak, J., Simmons, B., Ford, N. · 2014 · Clinical Infectious Diseases

Abstract

BACKGROUND: Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have similar mechanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) infection. Generic antiretrovirals are currently manufactured at very low prices, to treat 10 million people with HIV/AIDS in developing countries. METHODS: Four HCV DAAs, currently either in phase 3 development or recent approval (daclatasvir, sofosbuvir, simeprevir, faldaprevir), and ribavirin were classified by chemical structure, molecular weight, total daily dose, and complexity of synthesis. The likely range of manufacturing costs per gram of DAA were then projected as formulated product cost, based upon treating a minimum of 1 million patients annually (to arrive at volume demand) combined with an analysis of the complexity of synthesis and a 40% margin for formulation. Projections were then compared with actual costs of antiretrovirals with similar structures. RESULTS: Minimum manufacturing costs of antiretrovirals were US$0.2-$2.1 per gram. The complexity of chemical synthesis for HCV DAAs was ranked from lowest to highest: ribavirin, daclatasvir, sofosbuvir, faldaprevir, and simeprevir. Predicted manufacturing costs (US dollars) for 12-week courses of HCV DAAs were $21-$63 for ribavirin, $10-$30 for daclatasvir, $68-$136 for sofosbuvir, $100-$210 for faldaprevir, and $130-$270 for simeprevir. CONCLUSIONS: Within the next 15 years, large-scale manufacture of 2 or 3 drug combinations of HCV DAAs is feasible, with minimum target prices of $100-$250 per 12-week treatment course. These low prices could make widespread access to HCV treatment in low- and middle-income countries a realistic goal.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciu012

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 5

  1. 2013, Journal of hepatology, 58, S22
  2. 2012, Clinical Infectious Diseases, 54, 145
  3. 2012, Hepatology (Baltimore, Md.), 56, 230A
  4. 2012, Hepatology (Baltimore, Md.), 56, 306A
  5. 2012, Hepatology (Baltimore, Md.), 56, 308A

Cited by

See all 242

Metadata

Authors
Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N.
Affiliations
  • University of Liverpool (GB)
  • Howard University (US)
  • Imperial College London (GB)
  • University of Cape Town (ZA)
Corresponding author
Hill, A.
Venue
Clinical Infectious Diseases
Published
2014-01-06
Volume
58
Issue
7
Pages
928-936
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2163848297
Cited by
216
References
28
Citations by year
2026: 5 · 2025: 1 · 2024: 8 · 2023: 10 · 2022: 9 · 2021: 5 · 2020: 15 · 2019: 14 · 2018: 22 · 2017: 26 · 2016: 34 · 2015: 43 · 2014: 24
FWCI
23.90
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
hepatitis C, direct-acting antivirals, cost projections, daclatasvir, sofosbuvir, simeprevir, faldaprevir, ribavirin, generic drug production, treatment access, low- and middle-income countries, drug pricing
MeSH terms
Sofosbuvir, Simeprevir, Aminoisobutyric Acids, Antiviral Agents, Carbamates, Developing Countries, Drug Industry, Drug Therapy, Combination, Health Services Accessibility, Hepatitis C, Heterocyclic Compounds, 3-Ring, Humans, Imidazoles, Leucine, Oligopeptides, Proline, Pyrrolidines, Quinolines, Ribavirin, Sulfonamides, Thiazoles, Uridine Monophosphate, Valine, Hepacivirus, Anti-HIV Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries. https://app.cochat.ai/papers/10.1093/cid/ciu012
The paper
Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014). Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciu012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.